Mild cognitive impairment–amnestic type (MCI-AT) is mild, repeated memory loss. It lies between the normal memory loss of aging and the more serious conditions of dementia and Alzheimer’s disease (AD) . MCI-AT only involves problems with memory. Dementia and Alzheimer's involve loss of other cognitive abilities, such as:
People with MCI-AT who are over age 65 have a higher chance of developing dementia and Alzheimer's. However, many people with MCI-AT never develop these disorders. Some even return to normal.
Areas of the Brain
Copyright © Nucleus Medical Media, Inc.
These risk factors increase your chance of developing MCI-AT. Tell your doctor if you have any of these risk factors:
Research also suggests that these may be risk factors for MCI-AT:
The main symptom is frequent, ongoing memory loss beyond what is normally expected for your age. That means having more than small lapses of memory. If you have MCI-AT, you may:
The doctor will ask about your symptoms and medical history. The doctor may also talk with family members and caregivers. A physical exam will be done.
If you have this condition, you should have your cognitive abilities tested regularly.
Treatment is focused on:
Researchers are currently studying the effects that several medicines may have on slowing cognitive decline. Examples include donepezil , vitamin E, galantamine (Razadyne), among others. In some cases, low doses of lithium may be prescribed.
The following topics are being studied as ways to reduce the risk of cognitive decline:
RESOURCES:
American Psychiatric Association
http://www.psych.org
National Institute on Aging
http://www.nia.nih.gov
CANADIAN RESOURCES:
The Alzheimer Society of Canada
http://www.alzheimer.ca
Seniors Canada
http://www.seniors.gc.ca
References:
Birks J, Flicker L. Donepezil for mild cognitive impairment. Cochrane Database Syst Rev . 2006;3:CD006104.
DeKosky ST, Williamson JD, Fitzpatrick AL, et al. Ginko biloba for prevention of dementia: a randomized controlled trila. JAMA . 2008;300:2306-2308.
Feldman HH, Jacova C. Mild cognitive impairment. Am J Geriatr Psychiatry . 2005;13:645-655.
Gauthier S, Reisberg B, Zaudig M, et al. Mild cognitive impairment. Lancet . 2006;367:1262-1270.
Institute for the Study of Aging and International Longevity Center–USA (March 2001). Achieving and Maintaining Cognitive Vitality With Aging: A Workshop Report . New York, NY.
Mild cognitive impairment. EBSCO DynaMed website. Available at: http://www.ebscohost.com/dynamed/ . Updated January 28, 2013. Accessed February 19, 2013.
National Institute on Aging. 2011-2012 Alzheimer's Disease Progress Report . Available at: http://www.nia.nih.gov/alzheimers/publication/2011-2012-alzheimers-disease-progress-report . Accessed February 19, 2013.
Petersen RC. Mild cognitive impairment: current research and clinical implications. Semin Neurol . 2007;27.
Petersen RC, Roberts RO, Knopmann DS, et al. Mild cognitive impairment: ten years later. Arch Neurol . 2009;66(12):1447-1455.
Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology . 1999;56:303-308.
Last reviewed March 2013 by Michael Woods, MD
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © 2012 EBSCO Publishing All rights reserved.